458.49
price down icon0.29%   -1.32
pre-market  Vorhandelsmarkt:  458.51   0.02   +0.00%
loading

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

pulisher
04:14 AM

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool

04:14 AM
pulisher
04:02 AM

What drives Vertex Pharmaceuticals Incorporated stock priceConsistent triple returns - jammulinksnews.com

04:02 AM
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 20, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentMarket-leading growth rates - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockAccelerated wealth expansion - Jammu Links News

Jul 19, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive

Jul 15, 2025
pulisher
Jul 15, 2025

Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE

Jul 15, 2025
pulisher
Jul 15, 2025

NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment - geneonline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

(Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 11, 2025

Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com

Jul 11, 2025
pulisher
Jul 10, 2025

Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma

Jul 10, 2025
pulisher
Jul 09, 2025

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE

Jul 09, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire

Jul 08, 2025
pulisher
Jul 08, 2025

Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey

Jul 08, 2025
pulisher
Jul 08, 2025

FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

China Universal Asset Management Co. Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat

Jul 07, 2025
pulisher
Jul 03, 2025

Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY - Yahoo Finance

Jul 03, 2025
pulisher
Jul 02, 2025

VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025
pulisher
Jul 02, 2025

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek - Nasdaq

Jul 02, 2025
pulisher
Jul 02, 2025

Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access - Yahoo Finance

Jul 02, 2025
pulisher
Jul 01, 2025

Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU - Stocktwits

Jul 01, 2025
pulisher
Jul 01, 2025

, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Jul 01, 2025
pulisher
Jun 30, 2025

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? - Yahoo Finance

Jun 30, 2025
pulisher
Jun 29, 2025

H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results - Yahoo Finance

Jun 29, 2025
pulisher
Jun 27, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug - Yahoo Finance

Jun 27, 2025
pulisher
Jun 26, 2025

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance

Jun 26, 2025
pulisher
Jun 24, 2025

Journavx From Vertex Pharmaceuticals Inc - Pharmacy Times

Jun 24, 2025
pulisher
Jun 23, 2025

Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain - BioSpace

Jun 23, 2025
pulisher
Jun 21, 2025

Vertex posts additional trial data for type 1 diabetes therapy - Seeking Alpha

Jun 21, 2025
pulisher
Jun 20, 2025

Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake - Yahoo Finance

Jun 20, 2025
$545.53
price up icon 0.55%
$320.52
price down icon 0.00%
$566.14
price up icon 0.27%
biotechnology ONC
$291.93
price down icon 0.89%
$108.91
price down icon 1.01%
Kapitalisierung:     |  Volumen (24h):